VKTX Overview
Upcoming Projects (VKTX)
-
Evaluating the New Data from Viking Therapeutics’ (VKTX) VK2735 Obesity Program from ObesityWeek 2024
Ticker: VKTX
Execute By: Dec 31, 2024
Executed Projects (VKTX)
-
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 24, 2024 at 04:56 PM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic July 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Aug 01, 2024 at 10:42 AM EDT -
Exploring the potential for Viking Therapeutics' VK2809, a liver-selective thyroid hormone receptor beta agonist, in patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Ticker: VKTX
Executed On: Jul 19, 2024 at 03:30 PM EDT -
Exploring the Breakthrough of VK2735 in Metabolic Disorders: Insights from Viking Therapeutics' Phase 1 Study (oral formulation)
Ticker: VKTX
Executed On: May 07, 2024 at 01:00 PM EDT -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic April 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Apr 18, 2024 at 03:17 PM EDT -
Discussing the recent P2 Venture Trial data of Viking's VK273 with an Obesity Medicine Physician
Ticker: VKTX
Executed On: Mar 05, 2024 at 09:00 AM EST -
Quarterly Survey: Type 2 Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic January 2024
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jan 22, 2024 at 01:24 PM EST -
Quarterly Survey: Diabetes GLP-1 Treatments including LLY's Mounjaro and NVO's Ozempic October 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Oct 26, 2023 at 04:59 PM EDT -
Exploring the current treatment landscape and the future direction of available NASH specific drugs with the introduction of GLP-1 agonists
Tickers: MDGL, TERN, ETNB, VKTX
Executed On: Sep 19, 2023 at 10:00 AM EDT -
Quarterly Survey: Diabetes GLP-1 Treatments and LLY's Mounjaro and NVO's Ozempic July 2023
Tickers: LLY, NVO, AZN, VKTX
Executed On: Jul 25, 2023 at 05:46 PM EDT -
A Second Look: Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with a bariatric medicine specialist.
Ticker: VKTX
Executed On: Apr 25, 2023 at 04:30 PM EDT -
Discussing the potential of Viking therapeutics dual GLP-1/GIP Receptor Agonist, VK2735, in development for obesity and various metabolic disorders with an endocrinologist
Ticker: VKTX
Executed On: Apr 20, 2023 at 04:15 PM EDT
Upcoming & Overdue Catalysts (VKTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (VKTX)
-
Viking (VKTX) Releases Preliminary Results from Proof-of-Concept (POC) Study Assessing VK2809 in Glycogen Storage Disease Ia
Ticker: VKTX
Occurred on: Feb 09, 2017 -
Viking Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants
Ticker: VKTX
Occurred on: Apr 08, 2016
Strategic Initiatives (VKTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
